US EditionPublished • loading... • Updated
Johnson & Johnson Launches First Head-to-Head Study of IMAAVY in Myasthenia Gravis
Summary by MyChesCo
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Johnson & Johnson Launches First Head-to-Head Study of IMAAVY in Myasthenia Gravis
SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) announced plans to launch the first-ever head-to-head study comparing its FcRn blocker IMAAVY™ (nipocalimab-aahu) with efgartigimod in adults living with generalized myasthenia gravis (gMG). The Phase 3b EPIC trial will evaluate whether IMAAVY delivers superior disease control to efgartigimod among patients who have not previously received an FcRn blocker. The study will also feature a treatment-s…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
